Drug Trial Radar · NCT03943589
A Study of Imlifidase in Patients With Guillain-Barré Syndrome
Last checked: Nov 19, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Nov 12, 2019
Primary completion
Feb 27, 2024
Study completion Feb 27, 2024
Sponsor
- Lead sponsor
- Hansa Biopharma ABIndustry
- Sponsor type
- Industry
- First posted
- May 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study participants are patients which have been diagnosed with Guillain-Barré Syndrome (GBS) and are planned to receive treatment with intravenous immunoglobulin (IVIg). IVIg is a standard of care treatment for GBS patients. The patients in this study will be treated with the study medicine imlifidase on day 1, and with IVIg on days 3-7. The purpose of this study is to investigate the safety and effectiveness of imlifidase in patients diagnosed with GBS.
Conditions
- Guillain-Barré Syndrome (GBS)
Interventions
ImlifidaseDrug
All subjects will receive imlifidase (Day 1) prior to standard care IVIg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Guillain Barré Syndrome Disability Score (GBS DS) - Time to Improve by at Least 1 GradeTime frame: Baseline to Day 360
- Guillain Barré Syndrome Disability Score (GBS DS) - Time to Improve by at Least 2 GradesTime frame: Baseline to Day 360
- Guillain Barré Syndrome Disability Score (GBS DS) - Ability to Walk UnaidedTime frame: Baseline to Day 360
- Proportion of Patients Who Are Able to Run Over Time (GBS DS≤1)Time frame: Baseline to Day 360
- Mean MRC Sum Score Over TimeTime frame: Baseline until Day 180
- Change From Baseline in MRC Sum Score Over TimeTime frame: Baseline until Day 180
- Mean R-ODS Over TimeTime frame: Baseline to Day 360
- Change From Baseline in R-ODS Over TimeTime frame: Baseline to Day 360
- Days in HospitalTime frame: Baseline to Day 360
- Time in an ICUTime frame: Baseline until Day 360
- Need for Mechanical VentilationTime frame: Baseline until Day 180
- Patient's Health State Over Time as Assessed by EQ VASTime frame: Day 8, Day 15, Day 29, Day 57, Day 92, Day 180, and Day 360
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
CHU Bordeaux - Hôpital Pellegrin Tripode
Bordeaux, France
CHU de Limoges - Hôpital Dupuytren
Limoges, France
Hôpital de la Timone - Centre de référence des maladies neuromusculaires et de la SLA
Marseille, France
CHU de Montpellier, Hôpital Gui de Chauliac
Montpellier, France
Centre Hospitalier Universitaire de Nantes
Nantes, France
Service de neurologie, Hôpitaux Universitaires de Strasbourg
Strasbourg, France
CHU Le Kremlin-Bicêtre. Service Neurologie
Le Kremlin-Bicêtre, Paris, France
Amsterdam UMC
Amsterdam, Netherlands
Erasmus Medical Centre
Rotterdam, Netherlands
Queen Elizabeth University Hospital Glasgow
Glasgow, United Kingdom
Oxford University Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.